Necessity of induction agent modification for old age kidney transplant recipients
10.23876/j.krcp.23.068
- Author:
Kyeong Deok KIM
;
Kyo Won LEE
;
Jae Berm PARK
;
Woo Sung SIM
;
Manuel LIM
;
Eun Sung JEONG
;
Jieun KWON
;
Jaehun YANG
- Publication Type:Original Article
- From:Kidney Research and Clinical Practice
2025;44(2):349-360
- CountryRepublic of Korea
- Language:English
-
Abstract:
Immunosenescence gradually deteriorates the function of the immune system, making elderly patients susceptible to infection, while reducing rejection of organ transplants. Therefore, age-adaptive immunosuppression is necessary in the elderly. We evaluated clinical outcomes such as rejection and infection rate when using basiliximab and rabbit anti-thymocyte globulin (r-ATG) as induction agents in elderly and young organ transplant recipients. Methods: We retrospectively reviewed patients who underwent kidney transplantation (KT) between June 2011 and April 2019. We enrolled 704 adult KT patients and classified the patients into groups according to patient age. We compared the outcomes of infection and biopsy-proven acute rejection (BPAR) according to the type of induction agent (basiliximab and r-ATG [4.5 mg/kg]). Results: The patient group included 520 recipients (74.6%) in the younger recipient group and 179 recipients (25.4%) in the older recipient group. When r-ATG was used as an induction agent, BPAR within 6 months occurred less (p = 0.03); however, infections within 6 months were higher in older recipients. Deaths due to infection were more common in older recipients (p = 0.003). Conclusion: It may be necessary to use less intensive induction therapy for older recipients, of which dose reduction of r-ATG is one option.
